Pharmion says it is planning to use a platinum-based drug in its treatment of prostate cancer.

The drug manufacturer is hoping to receive the go-ahead from the European Medicines Authority (EMEA) to use satraplatin for the treatment of second-line hormone refractory prostate cancer from the beginning of next year.

It is the only oral platinum based treatment that is currently in the advanced stages of clinical development.

"We are committed to providing the submission to the EMEA in as timely a fashion as possible, pending the results from a final analysis," said Patrick Mahaffy, Pharmion's president and chief executive.

It is hoped the drug will also be used in the treatment of a number of other illnesses.


Ÿ Adfero Ltd